Advertisement

Polymerisation of a T Cell Epitope with an Immunostimulatory C3d Peptide Sequence Enhances Antigen Specific T Cell Responses

  • Neil M. O’Brien-Simpson
  • Troy J. Attard
  • Baihui Zheng
  • Katrina A. Walsh
  • Eric C. Reynolds
Article
  • 194 Downloads

Abstract

The complement protein C3d and C3d derived peptides that bind CD21 are known to enhance immunity to co-immunised antigens. In this study we have synthesised the minimal CD21 binding sequence of C3d (1227LYNVEA1232) as mono, di and tri tandem repeats and derivatised the N-terminus with an acryloyl moiety. These acryloyl-(C3d) n peptides were co-polymerised with a acryloyl-T cell epitope (PAS1K) from the Porphyromonas gingivalis antigen the RgpA–Kgp proteinase–adhesin complex. The ability of C3d containing polymers to enhance T cell immunity in vitro and in vivo was evaluated. When used to stimulate in vitro PAS1K-primed or RgpA–Kgp complex-primed T cells the C3d containing PAS1K polymers induced a mixed and significantly (p < 0.05) higher IL-4 and IFNγ T cell response compared to that induced by the PAS1K peptide or polymer. PAS1K polymers containing tandem repeats of C3d induced a significantly (p < 0.05) stronger maximal proliferative response, at the same antigenic dose, compared to that induced by the PAS1K peptide or polymer. When used as immunogens to prime T cells all of the C3d containing PAS1K polymers induced a dominant IFNγ T cell response and reduced the antigen dose required for maximal proliferation 150-fold compared to that required for the PAS1K-peptide or polymer primed T cells. In conclusion, the 6 residue sequence LYNVEA from C3d is sufficient to enhance immunity to an antigen and that the effect is more pronounced when C3d is part of the immunising antigen rather than an in vitro stimulating antigen.

Keywords

C3d complement Peptide synthesis Peptide polymers T cell immune responses 

Notes

Acknowledgments

We also wish to thank Ms Jenny Davis for the animal welfare and handling. This work was supported by NHMRC Grants: APP1029878 and APP1008106.

References

  1. Allison AC (1998) The mode of action of immunological adjuvants. Dev Biol Stand 92:3–11PubMedGoogle Scholar
  2. Bergmann-Leitner ES, Leitner WW, Tsokos GC (2006) Complement 3d: from molecular adjuvant to target of immune escape mechanisms. Clin Immunol 121:177–185PubMedCrossRefGoogle Scholar
  3. Bergmann-Leitner ES, Duncan EH, Leitner WW, Neutzner A, Savranskaya T, Angov E, Tsokos GC (2007) C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine 25:7732–7736PubMedCrossRefGoogle Scholar
  4. Bower JF, Ross TM (2006) A minimum CR2 binding domain of C3d enhances immunity following vaccination. Adv Exp Med Biol 586:249–264PubMedCrossRefGoogle Scholar
  5. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348–350PubMedCrossRefGoogle Scholar
  6. Dyrberg T, Oldstone MB (1986) Peptides as antigens. Importance of orientation. J Exp Med 164:1344–1349PubMedCrossRefGoogle Scholar
  7. Falk K, Rotzschke O, Strominger JL (2000) Antigen-specific elimination of T cells induced by oligomerized hemagglutinin (HA) 306–318. Eur J Immunol 30:3012–3020PubMedCrossRefGoogle Scholar
  8. Fearon DT (1998) The complement system and adaptive immunity. Semin Immunol 10:355–361PubMedCrossRefGoogle Scholar
  9. Fitzmaurice CJ, Brown LE, Kronin V, Jackson DC (2000) The geometry of synthetic peptide-based immunogens affects the efficiency of T cell stimulation by professional antigen-presenting cells. Int Immunol 12:527–535PubMedCrossRefGoogle Scholar
  10. Frade R, Hermann J, Barel M (1992) A 16 amino acid synthetic peptide derived from human C3d triggers proliferation and specific tyrosine phosphorylation of transformed CR2-positive human lymphocytes and of normal resting B lymphocytes. Biochem Biophys Res Commun 188:833–842PubMedCrossRefGoogle Scholar
  11. Green TD, Montefiori DC, Ross TM (2003) Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 77:2046–2055PubMedCrossRefGoogle Scholar
  12. Haas KM, Toapanta FR, Oliver JA, Poe JC, Weis JH, Karp DR, Bower JF, Ross TM, Tedder TF (2004) Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J Immunol 172:5833–5837PubMedGoogle Scholar
  13. Hancock WS, Battersby JE (1976) A new micro-test for the detection of incomplete coupling reactions in solid-phase peptide synthesis using 2,4,6-trinitrobenzene-sulphonic acid. Anal Biochem 71:260PubMedCrossRefGoogle Scholar
  14. Hourcade D, Holers VM, Atkinson JP (1989) The regulators of complement activation (RCA) gene cluster. Adv Immunol 45:381–416PubMedCrossRefGoogle Scholar
  15. Jackson DC, O’ Brien-Simpson N, Ede NJ, Brown LE (1997) Free radical induced polymerization of synthetic peptides into polymeric immunogens. Vaccine 15:1697–1705PubMedCrossRefGoogle Scholar
  16. Jung MC, Hartmann B, Gerlach JT, Diepolder H, Gruber R, Schraut W, Gruner N, Zachoval R, Hoffmann R, Santantonio T, Wachtler M, Pape GR (1999) Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 261:165–172PubMedCrossRefGoogle Scholar
  17. Kerekes K, Prechl J, Bajtay Z, Jozsi M, Erdei A (1998) A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells. Int Immunol 10:1923–1930PubMedCrossRefGoogle Scholar
  18. Knopf PM, Rivera DS, Hai SH, McMurry J, Martin W, De Groot AS (2008) Novel function of complement C3d as an autologous helper T-cell target. Immunol Cell Biol 86:221–225PubMedCrossRefGoogle Scholar
  19. Lambris JD, Ganu VS, Hirani S, Muller-Eberhard HJ (1985) Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci USA 82:4235–4239PubMedCrossRefGoogle Scholar
  20. LaSalle JM, Hafler DA (1994) T cell anergy. FASEB J 8:601–608PubMedGoogle Scholar
  21. Levy E, Ambrus J, Kahl L, Molina H, Tung K, Holers VM (1992) T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Clin Exp Immunol 90:235–244PubMedCrossRefGoogle Scholar
  22. Lou D, Kohler H (1998) Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide. Nat Biotechnol 16:458–462PubMedCrossRefGoogle Scholar
  23. Lu YA, Clavijo P, Galantino M, Shen ZY, Liu W, Tam JP (1991) Chemically unambiguous peptide immunogen: preparation, orientation and antigenicity of purified peptide conjugated to the multiple antigen peptide system. Mol Immunol 28:623–630PubMedCrossRefGoogle Scholar
  24. Macatangay BJ, Zheng L, Rinaldo CR, Landay AL, Pollard RB, Pahwa S, Lederman MM, Bucy RP (2010) Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181. Clin Vaccine Immunol 17:1452–1459PubMedCrossRefGoogle Scholar
  25. Masilamani M, von Seydlitz E, Bastmeyer M, Illges H (2002) T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression. Immunobiology 206:528–536PubMedCrossRefGoogle Scholar
  26. Mitsuyoshi JK, Hu Y, Test ST (2005) Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide. Infect Immun 73:7311–7316PubMedCrossRefGoogle Scholar
  27. Mkrtichyan M, Ghochikyan A, Movsesyan N, Karapetyan A, Begoyan G, Yu J, Glenn GM, Ross TM, Agadjanyan MG, Cribbs DH (2008) Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization. DNA Cell Biol 27:19–24PubMedCrossRefGoogle Scholar
  28. Molnar E, Prechl J, Erdei A (2008) Novel roles for murine complement receptors type 1 and 2 II. Expression and function of CR1/2 on murine mesenteric lymph node T cells. Immunol Lett 116:163–167PubMedCrossRefGoogle Scholar
  29. Mongini PK, Vilensky MA, Highet PF, Inman JK (1997) The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J Immunol 159:3782–3791PubMedGoogle Scholar
  30. O’Brien-Simpson N, Ede NJ, Brown LE, Swan J, Jackson DC (1997) Polymerization of unprotected synthetic peptides: a view toward synthetic peptide vaccines. J Am Chem Soc 119:1183CrossRefGoogle Scholar
  31. Partidos C, Stanley C, Steward M (1992) The effect of orientation of epitopes on the immunogenicity of chimeric synthetic peptides representing measles virus protein sequences. Mol Immunol 29:651–658PubMedCrossRefGoogle Scholar
  32. Pathirana RD, O’Brien-Simpson NM, Veith PD, Riley PF, Reynolds EC (2006) Characterization of proteinase-adhesin complexes of Porphyromonas gingivalis. Microbiology 152:2381–2394PubMedCrossRefGoogle Scholar
  33. Rejmanova P, Kopecek J, Pohl J, Baudys M, Kostka V (1983) Polymers containing enzymatically degradable bonds, 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B†‡. Makromolekule Chemie 184:2009CrossRefGoogle Scholar
  34. Roozendaal R, Carroll MC (2007) Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 219:157–166PubMedCrossRefGoogle Scholar
  35. Sandler SR, Karo W (1992) Polymer synthesis. Academic Press, BostonGoogle Scholar
  36. Sarobe P, Lasarte JJ, Larrea E, Golvano JJ, Prieto I, Gullon A, Prieto J, Borras-Cuesta F (1993) Enhancement of peptide immunogenicity by insertion of a cathepsin B cleavage site between determinants recognized by B and T cells. Res Immunol 144:257–262PubMedCrossRefGoogle Scholar
  37. Schultes BC, Whiteside TL (2003) Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay. J Immunol Methods 279:1–15PubMedCrossRefGoogle Scholar
  38. Servis C, Lambris JD (1989) C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells. J Immunol 142:2207–2212PubMedGoogle Scholar
  39. Sinha SK, Todd SC, Hedrick JA, Speiser CL, Lambris JD, Tsoukas CD (1993) Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript. J Immunol 150:5311–5320PubMedGoogle Scholar
  40. Suradhat S, Braun RP, Lewis PJ, Babiuk LA, van Drunen Littel-van den Hurk S, Griebel PJ, Baca-Estrada ME (2001) Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet Immunol Immunopathol 83:79–92PubMedCrossRefGoogle Scholar
  41. Toapanta FR, Ross TM (2006) Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res 36:197–210PubMedCrossRefGoogle Scholar
  42. Troye-Blomberg M, Romero P, Patarroyo ME, Bjorkman A, Perlmann P (1984) Regulation of the immune response in Plasmodium falciparum malaria. III. Proliferative response to antigen in vitro and subset composition of T cells from patients with acute infection or from immune donors. Clin Exp Immunol 58:380–387PubMedGoogle Scholar
  43. Tsokos GC, Lambris JD, Finkelman FD, Anastassiou ED, June CH (1990) Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. J Immunol 144:1640–1645PubMedGoogle Scholar
  44. Wang XL, Zhao XR, Yu M, Yuan MM, Yao XY, Li DJ (2006) Gene conjugation of molecular adjuvant C3d3 to hCGbeta increased the anti-hCGbeta Th2 and humoral immune response in DNA immunization. J Gene Med 8:498–505PubMedCrossRefGoogle Scholar
  45. Zabel MD, Weis JH (2001) Cell-specific regulation of the CD21 gene. Int Immunopharmacol 1:483–493PubMedCrossRefGoogle Scholar
  46. Zhang D, Xia Q, Wu J, Liu D, Wang X, Niu Z (2011) Construction and immunogenicity of DNA vaccines encoding fusion protein of murine complement C3d–p28 and GP5 gene of porcine reproductive and respiratory syndrome virus. Vaccine 29:629–635PubMedCrossRefGoogle Scholar
  47. Zou Y, Lin J, Dai L, Pan R (1993) Group-transfer block copolymerization by bifunctional initiators. Gaodeng Xuexiao Huaxue Xuebao 14:294–295Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Neil M. O’Brien-Simpson
    • 1
  • Troy J. Attard
    • 1
  • Baihui Zheng
    • 1
  • Katrina A. Walsh
    • 1
  • Eric C. Reynolds
    • 1
  1. 1.Oral Health CRC, Melbourne Dental School, Bio21 Institute, The University of MelbourneMelbourneAustralia

Personalised recommendations